Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95167 trials found · Page 156 of 4759
-
New drug duo aims to tame blood disorder when standard meds fail
Disease control Recruiting nowThis study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the po…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
AI takes on breast cancer: could a computer predict the best second treatment?
Disease control Recruiting nowThe goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they have progressed on the first CDK4/6 inhibitor. Patient…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 16, 2026 13:06 UTC
-
New scan-guided radiation aims to cut side effects in recurrent prostate cancer
Disease control Recruiting nowPurpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 44% historical rate, while maintaining cancer control after prostatectomy.Population/Eligibility: Adult men ≥30 years with…
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 16, 2026 13:07 UTC
-
New hope for PAD patients: experimental drugs aim to stop deadly clots after leg surgery
Disease control Not yet recruitingThis study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 16, 2026 13:03 UTC
-
New triple-drug combo aims to improve leukemia treatment with fewer side effects
Disease control Recruiting nowThe purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. …
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated May 16, 2026 13:08 UTC
-
New drug cocktail targets Hard-to-Treat nasopharyngeal cancer
Disease control Not yet recruitingTo explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereb…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New pill combo could boost CAR-T power against tough lymphoma
Disease control Not yet recruitingThe purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New pill aims to keep breast cancer from coming back in women with certain genes
Disease control Not yet recruitingThe study is a randomized, open-label, multicenter phase II clinical trial of the efficacy and safety of fluzopanib in the adjuvant treatment of early breast cancer using germline mutations in homologous recombination repair pathway genes. Study design Patients will be randomized…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Triple therapy takes on advanced lung cancer in early trial
Disease control Not yet recruitingThis is an open-label, single center, one cohort, non-randomized, phase II study. The aim of the study is to evaluate the efficacy and safety of the combination of nivolumab and ipilimumab with nogapendekin alfa inbakicept in patients with stage IV or recurrent non-small cell lun…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 16, 2026 13:07 UTC
-
Radiation and drug combo takes on Hard-to-Treat myeloma
Disease control Recruiting nowTo learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for lung cancer patients whose immunotherapy stopped working
Disease control Not yet recruitingThis is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary immune resistance and high YAP protein expression.
Phase: PHASE2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Stomach cancer shot could replace IV drip in major trial
Disease control Not yet recruitingA Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Triple-Drug attack before surgery aims to beat pancreatic cancer
Disease control Not yet recruitingThe goal of this clinical trial is to learn if surufatinib (VEGFR-TKI) plus toripalimab (PD-1 inhibitor) and mFOLFIRINOX (chemotherapy) works as neoadjuvant therapy for patients with high-risk or borderline resectable pancreatic cancer. It will also learn about the safety of the …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug aims to shield cancer patients from chemo side effects
Disease control Not yet recruitingThe goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small c…
Phase: PHASE3 • Sponsor: Pharmacosmos A/S • Aim: Disease control
Last updated May 16, 2026 13:06 UTC
-
New hope for hard-to-treat cancers: experimental drug targets KRAS G12D mutation
Disease control Recruiting nowThis is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo therapy shows promise for Hard-to-Treat bile duct cancer
Disease control Recruiting nowBiliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patien…
Phase: NA • Sponsor: Peking University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New triple combo aims to hold back advanced breast cancer
Disease control Not yet recruitingThis is a Prospective, Single-Arm, Observational, Real-World Study. The purpose of this study is to evaluate the safety and efficacy of pyrotinib combined with trastuzumab and pertuzumab for maintenance therapy in HER2-positive advanced breast cancer in the real-world setting.
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for elderly lymphoma patients: drug combo targets cancer without harsh chemo
Disease control Recruiting nowThis is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 16, 2026 13:07 UTC
-
Stroke drug combo shows promise in reducing brain damage after clot removal
Disease control Recruiting nowThe purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion pati…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New hope for older AML patients: drug combo aims for remission without harsh chemo
Disease control Not yet recruitingThis study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled. The Simon two-stage design will be adopted to control the t…
Phase: PHASE2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated May 11, 2026 20:47 UTC